BioLargo, Inc.
BLGO
$0.2365
$0.00351.50%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 45.40% | 85.73% | 91.40% | 52.93% | 107.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.40% | 85.73% | 91.40% | 52.93% | 107.78% |
| Cost of Revenue | 63.33% | 109.01% | 100.68% | 47.57% | 100.93% |
| Gross Profit | 27.68% | 62.92% | 81.91% | 58.75% | 115.03% |
| SG&A Expenses | 15.51% | 17.08% | 34.45% | 29.29% | 19.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -105.88% | -425.00% | 120.63% | 120.63% |
| Total Operating Expenses | 34.60% | 47.75% | 58.56% | 41.17% | 49.12% |
| Operating Income | -3.14% | 30.87% | 10.28% | -15.03% | 18.18% |
| Income Before Tax | 6.48% | 27.82% | 6.67% | -20.75% | 9.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.48% | 27.82% | 6.67% | -20.75% | 9.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 70.02% | 29.52% | 7.95% | 24.46% | 73.60% |
| Net Income | 31.45% | 45.21% | 12.25% | -19.52% | 21.66% |
| EBIT | -3.14% | 30.87% | 10.28% | -15.03% | 18.18% |
| EBITDA | -1.95% | 31.88% | 11.48% | -13.93% | 19.48% |
| EPS Basic | 34.15% | 47.45% | 15.79% | -13.27% | 26.35% |
| Normalized Basic EPS | 46.15% | 70.77% | 28.00% | -3.85% | 45.26% |
| EPS Diluted | 34.15% | 47.45% | 15.79% | -13.27% | 26.35% |
| Normalized Diluted EPS | 46.15% | 70.77% | 28.00% | -3.85% | 45.26% |
| Average Basic Shares Outstanding | 4.26% | 4.61% | 5.10% | 5.89% | 6.58% |
| Average Diluted Shares Outstanding | 4.26% | 4.61% | 5.10% | 5.89% | 6.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |